Cardioprotective and antiatherogenic age-dependent growth differentiation factor 11 in patients with arterial hypertension in combination with obesity
Journal Title: Український терапевтичний журнал - Year 2019, Vol 0, Issue 1
Abstract
Objective — to study the features of changes in the levels of growth differentiation factor 11 (FDR 11) in the blood of patients with arterial hypertension (AH) with abdominal obesity (AO) in comparison with the levels of this factor in practically healthy individuals and in patients with AH without obesity, and to establish the relationships between blood FDR 11 levels with the major risk factors and asymptomatic target organ damage. Materials and methods. The examinations were performed on 51 patients (29 men and 22 women) with AH stage II, 2—3 degrees in combination with AO І—ІІ degrees aged 45 to 69 years and 17 patients (10 men and 7 women) with AH without obesity aged 45 to 69 years. The control group consisted of 20 practically healthy individuals (12 men and 8 women) aged 35 to 49 years. All patients underwent routine clinical, laboratory and instrumental examination. The blood FDR 11 levels were determined by ELISA using commercial Cloude-Clone Corp, Houston, USA. Statistical processing of the obtained results was carried out using the Ехсеl software packages. Results and discussion. It has been revealed that in patients with AH and AO the blood FDR 11 levels were significantly lower than in practically healthy individuals and in patients with AH without obesity. At the same time, blood FDR 11 levels in patients with AH without obesity did not significantly differ from the levels of this factor in practically healthy individuals. It has been established that blood FDR 11 levels in patients with AO with more severe AH (3 degree) were significantly lower than in patients of this group with less severe AH (2 degree). In contrast to the patients with AH and AO, no significant difference in FDR 11 levels depending on the AH severity was defined for the patients with AH without obesity. The dependence of blood FDR 11 levels on the presence or absence of hypertensive heart (HH) in patients with AH and AO was revealed. It has been established that blood FDR 11 levels in patients with AH and AO, who developed HH, were significantly lower than in patients of this group without signs of this heart damage. There was no similar pattern in the changes in blood levels of FDR 11 among patients with AH without obesity. Conclusions. In patients with AH, combined with AO, a significant decrease in the level of powerful cardioprotective and antiatherogenic age-dependent factor-FDR 11 was established in comparison with healthy individuals. In addition, in this category of patients, further decrease in the blood level of this factor was revealed with the progression of AH and with the development of such specific hypertensive heart damage as hypertensive heart.
Authors and Affiliations
S. M. Koval, I. O. Snihurska, D. K. Miloslavsky, M. Yu. Penkova, V. Yu. Galchinska, O. M. Schenyavska
Keywords
Related Articles
- EP ID EP586672
- DOI 10.30978/UTJ2019-1-33
- Views 118
- Downloads 0
Age-related aspects of bone tissue condition at chronic pancreatitis
The fact that chronic pancreatitis (СP) affects mostly patients of employable age is one of the important factors of its social significance. Objective — to study the state of bone tissue of patients with СP of various a...
The relationship between prolactin levels, sleep disorders and the effectiveness of glycaemia correction in patients with hypertension and type 2 diabetes mellitus
Objective — to assess sleep disorders in patients with hypertension and type 2 diabetes mellitus and to establish the role of prolactin in the formation of these changes. Materials and methods. The study included 63 pati...
Life and destiny of the creator of domestic insulin V. M. Kogan—Yasnyi (to the 130th anniversary of the birth)
-
Matrix metalloproteinase-9 and connective tissue growth factor and their role in progression of hepato-myocardial fibrosis in patients with stable coronary heart disease combined with nonalcoholic fatty liver disease
Objective — to determine the regularities of the stable coronary heart disease (CHD) progression in condition of the formation of hepatomyocardial fibrosis by serum levels of matrix metalloproteinase-9 (MMP-9) and conne...
The model of adverse course of heart failure with account of the thyroid status of patients
Objective — to determine the predictors of adverse course of heart failure (HF) with account of the thyroid status of patients. Materials and methods. The study involved 157 patients with HF (and previous myocardial infa...